Cantargia AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.01.18	European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Hematological Cancers (PR Newswire)
19.01.18	Cantargia's European Patent for Solid Tumours Remains in Force (PR Newswire)
09.01.18	European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Solid Tumours (PR Newswire)
05.01.18	Cantargia Receives Patent Approval in China for Antibody Treatment Against IL1RAP in Solid Tumours (PR Newswire)
04.01.18	Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Solid Tumours (PR Newswire)
28.12.17	Automotive Composite Market (2017-2025): Analysis by Product, Application & Region (PR Newswire)
10.11.17	Notice of Extraordinary General Meeting in Cantargia AB (publ) (PR Newswire)
08.11.17	Cantargia Publishes Interim Report for Third Quarter of 2017 (PR Newswire)
23.08.17	Cantargia Publishes Half Year Report (PR Newswire)
03.11.16	Cantargia AB: Studies Using Cantargia's Antibodies in Models of Chronic Myeloid Leukaemia Presented at the American Society of Hematology (Businesswire)
24.10.16	Cantargia AB: Cantargia Raises MSEK 24.6 Through Exercise of Warrants (Businesswire)
20.10.16	Cantargia AB: Cantargia to Present New Data from Preclinical Studies with CAN04 in Non-Small Cell Lung Cancer (Businesswire)
20.09.16	Cantargia prepares intensified development strategy and capital raising (Businesswire)
24.08.16	Cantargia AB: Cantargia Interim Report January – June 2016 (Businesswire)
22.08.16	Cantargia AB: Cantargia Raises kSEK 250 Through Exercise of Warrants (Businesswire)
15.07.16	Cantargia AB: Cantargia Obtains a Granted Patent from USPTO Concerning Il1RAP in Solid Tumors (Businesswire)
10.06.16	Cantargia AB: Cantargia’s CAN04 product candidate show very good safety at high dose levels, paving the way for final GLP toxicity study in autumn 2016 (Businesswire)
10.06.16	Cantargia AB: Cantargia receives Notice of Allowance from USPTO on IL1RAP in solid tumours (Businesswire)
08.06.16	Cantargia AB: Cantargia receives patent approval in Japan for solid tumours (Businesswire)
08.06.16	Cantargia AB: Cantargia receives Notice of Allowance from USPTO on IL1RAP in acute lymphatic leukemia (Businesswire)
16.05.16	Cantargia Interim Report January – March 2016 (Businesswire)
20.04.16	Cantargia AB: Cantargia raises SEK 31.4 million through exercise of warrants of series TO 1 and TO 3 (Businesswire)
21.03.16	Cantargia AB: Cantargia Receives Patent Approval in Japan and Mexico (Businesswire)
10.03.16	Cantargia AB: Cantargia Secures Exercise of Warrants of Series TO 1 (Businesswire)
09.03.16	Cantargia AB’s CAN04 Product Candidate Shows Good Safety after Repeated Doses in New Toxicity Study (Businesswire)
01.03.16	Cantargia Year-End Report January – December 2015 (Businesswire)
03.02.16	Cantargia Patent Granted in Australia (Businesswire)
04.01.16	Cantargia Patent Granted by the European Patent Office (Businesswire)
01.12.15	Cantargia AB: Exercise of Warrants of Series 2010:1 (Businesswire)
17.11.15	Cantargia AB: Cantargia Interim Report for the Period 1 July 2015 – 30 September 2015 Available (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Cantargia AB

Aktien Top/Flop

Meistgelesene Nachrichten